Information regarding Investor Grievance Redressal Mechanism in Accordance with SEBI Circular No SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2024/50 dated 21st May 2024
Dear Client, For any general queries, you may contact us via email clients@dvia.in or call us on 8591426656. In case of any grievance / complaint against us, please contact our Compliance / Grievance Officer: Vivek Agarwall (Email: vivek@dvia.in / Mob: 9920803822)
You may also approach our Principal Officer - Deepak Bakliwal (Email: deepak@dvia.in / Mob: 9987686641)
If not satisfied with the response of the investment adviser you can lodge your grievances with SEBI at http://scores.gov.in or you may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575.
| Received From | Pending- last month | Received | Resolved* | Total Pending# | Pending > 3M | Avg. resolution time^ |
|---|---|---|---|---|---|---|
| Directly from Investors | 0 | 0 | 0 | 0 | 0 | 0 |
| SEBI Scores | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Sources | 0 | 0 | 0 | 0 | 0 | 0 |
| Grand Total | 0 | 0 | 0 | 0 | 0 | 0 |
| Month | Carried Forward | Received | Resolved* | Pending# |
|---|---|---|---|---|
| December-2023 | 0 | 0 | 0 | 0 |
| January-2024 | 0 | 0 | 0 | 0 |
| February-2024 | 0 | 0 | 0 | 0 |
| March-2024 | 0 | 0 | 0 | 0 |
| April-2024 | 0 | 0 | 0 | 0 |
| May-2024 | 0 | 0 | 0 | 0 |
| June-2024 | 0 | 0 | 0 | 0 |
| July-2024 | 0 | 0 | 0 | 0 |
| August-2024 | 0 | 0 | 0 | 0 |
| September-2024 | 0 | 0 | 0 | 0 |
| October-2024 | 0 | 0 | 0 | 0 |
| November-2024 | 0 | 0 | 0 | 0 |
| Year | Carried Forward | Received | Resolved* | Pending |
|---|---|---|---|---|
| 2021-22 | 0 | 0 | 0 | 0 |
| 2022-23 | 0 | 0 | 0 | 0 |
| 2023-24 | 0 | 0 | 0 | 0 |
| 2024-25 | 0 | 0 | 0 | 0 |
| Grand Total | 0 | 0 | 0 | 0 |
| Sr. no | Financial Year | Compliance Audit Status | Remarks, If any |
|---|---|---|---|
| 1 | FY 2020-21 | Not Conducted | Not Applicable as approval for RIA was received in Oct 2021 |
| 2 | FY 2021-22 | Conducted | No adverse observations |
| 3 | FY 2022-23 | Conducted | No adverse observations |
| 4 | FY 2023-24 | Conducted | No adverse observations |
